Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback